Drug company GlaxoSmithKline is out a hefty $3 billion after pleading guilty to promoting drugs for uses the FDA hasn't approved, the Justice Department said Monday. On the docket of crimes for which they're paying so dearly: The company advertised depression-treating Paxil to children even though it had only been approved for adults, and it promoted Wellbutrin, approved for depression, to treat sexual dysfunction, weight-control, addiction, and ADD. It also didn't report safety data on the diabetes drug Avandia, which carries warnings about increased risk of heart disease. 

Off-label marketing, as it's known, seems (lucky for the Justice Department) like a crime that by definition cannot be committed in secret: One breaks the law by "marketing" products, thus creating a massive paper trail. So Glaxo probably should have been more cautious. The $3 billion plea deal makes this the third largest health care fraud settlement in U.S. history, Justice said Monday, and to put that in context, the company reported an after-tax earning of $8.32 billion in 2011. So, that $3 billion seems like it'll be a pretty big dent in the 2012 figure. 

Want to add to this story? Let us know in comments or send an email to the author at erandall at theatlantic dot com. You can share ideas for stories on the Open Wire.